Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Long-Term Deferred Tax: 2022-2024

  • ProQR Therapeutics N.V's Long-Term Deferred Tax fell 18.73% to $3.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.5 million, marking a year-over-year decrease of 18.73%. This contributed to the annual value of $3.5 million for FY2024, which is 19.17% down from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Long-Term Deferred Tax of $3.5 million as of Q4 2024, which was down 18.73% from $4.3 million recorded in Q4 2023.
  • ProQR Therapeutics N.V's Long-Term Deferred Tax's 5-year high stood at $4.3 million during Q4 2023, with a 5-year trough of $3.5 million in Q4 2024.
  • Over the past 3 years, ProQR Therapeutics N.V's median Long-Term Deferred Tax value was $4.0 million (recorded in 2022), while the average stood at $3.9 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first increased by 7.13% in 2023, then declined by 18.73% in 2024.
  • ProQR Therapeutics N.V's Long-Term Deferred Tax (Quarterly) stood at $4.0 million in 2022, then rose by 7.13% to $4.3 million in 2023, then decreased by 18.73% to $3.5 million in 2024.
  • Its Long-Term Deferred Tax stands at $3.5 million for Q4 2024, versus $4.3 million for Q4 2023 and $4.0 million for Q4 2022.